<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454401</url>
  </required_header>
  <id_info>
    <org_study_id>H-4-2010-090</org_study_id>
    <nct_id>NCT01454401</nct_id>
  </id_info>
  <brief_title>LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers</brief_title>
  <official_title>LeucoPatch™ Study. A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reapplix</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reapplix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LeucoPatch™ study goal is to investigate whether the fully autologous growth
      factor-containing dressing LeucoPatch™ has a positive effect on healing rates of diabetic
      foot ulcers. The study seeks to gather data for comparison with previous data from similar
      wounds (historical controls). By subgrouping of the treated wounds (similar to the historical
      controls used) an assessment of which of the patient and wound-related factors that might
      indicate a beneficial effect of LeucoPatch™ is sought.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary: Treatment Study

      The goal of the LeucoPatch ™ study is to investigate the effect of LeucoPatch ™ in diabetic
      foot ulcer. LeucoPatch ™ is a biologically active dressings which are made solely by the
      patient's own blood (autologous). It is produced in the CE (European Conformity) marked
      LeucoPatch™ Device and contains no additives. In this treatment study up to 75 typical
      diabetic patients with foot ulcers are included. These wounds are typically chronic and lead
      to reduced quality of life and ability to work, and extensive treatment costs. Furthermore,
      these wounds often lead to amputations.The study is a multicenter study in which up to 10
      wound clinics are expected to be involved.

      The primary endpoint is time to complete healing, the secondary endpoint is change in wound
      size.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ulcer Healing Within 20 Weeks</measure>
    <time_frame>20 weeks</time_frame>
    <description>Number of the patients achieved complete epithelialization at 20 weeks in the ITT population and in the PP population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ulcer Healing Within 12 Weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of the patients achieved complete epithelialisation at 12 weeks (ITT population) and the percentage respectively in the PP population</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Weekly LeucoPatch treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Weekly treatment of diabetic foot ulcers with LeucoPatch</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LeucoPatch treatment</intervention_name>
    <description>weekly</description>
    <arm_group_label>Weekly LeucoPatch treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Type I or Type II Diabetes

          -  Age of wounds &gt; 6 weeks

          -  Wound area &lt;10 cm2

          -  Wounds: Texas degree ≤ type IIa

          -  Perfusion status: toe pressure&gt; 30 mmHg, or transcutaneous oxygen measurement (TcPO2)&gt;
             30 mmHg on the foot (measured within the last 3 months) or palpable foot pulse
             (equivalent to&gt; 60 mmHg)

          -  Diabetes control: HbA1c &lt;12%

          -  Adequate off-loading (Walker, therapy sandals etc.)

          -  The patient can adhere to the treatment protocol and is expected to conclude the study

          -  Written informed consent

        Exclusion Criteria:

          -  Non-Danish or Swedish speaking

          -  Dementia

          -  Pregnant or nursing women

          -  The patient cannot tolerate blood donation

          -  Hemoglobin : &lt; 6,5 mmol/l or 105 g/l

          -  Haemophilia, Sickle cell anemia, severe thrombocytopenia, and leukemia or blood
             dyscrasias.

          -  Patient on dialysis

          -  Clinical signs of infection - including osteomyelitis (probe to bone).

          -  Necrosis of the wound

          -  40% change (+/-) in ulcer area in a 2-week run-in period with optimal therapy.

          -  Blood vessel reconstruction within the last 4 weeks.

          -  Participation in other clinical wound healing studies in the last 30 days.

          -  Failure to comply with study protocol in the 2-week run-in period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tonny Karlsmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Dermatology D, Bispebjerg Hospital,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Joergensen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Dermatology D, Bispebjerg Hospital,Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Marie Nielsen, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Center for Wound Healing, Odense University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lise Tarnow, MD,MDSc</last_name>
    <role>Study Director</role>
    <affiliation>Steno Diabetes Center, Niels Steensensvej 2, 2820 Gentofte, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariusz Zakrzewski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vascular Center, wound clinic,Kolding Hospital, Skovvangen 2-8,6000 Kolding, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niels Ejskjær, MD. PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Afd.M Endocrinology, Aarhus University Hospital,. Noerrebrogade 44,8000 Århuc C, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morten Michelsen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Orthopaedic Surgery Infirmary, Sårcenter. Herlev Hospital,Herlev Ringvej 75,2730 Herlev, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magnus Löndahl, MD. PhD</last_name>
    <role>Study Director</role>
    <affiliation>Skane University Hospital, Department of Endocrinology, Diabetes Foot Ulcer Clinic, Hudhuset Getingevägen 4, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Nilsson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ängelholm Hospital, Department of Medicine, Diabetes Foot Ulcer Clinic, 262 81 Ängelholm Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Knowledge Center for woundhealing, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital, Orthopaedic Surgery Infirmary, Wound Clinic</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vascular Center, Wound Clinic Kolding Hospital</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University center for woundhealing, Odense Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital, Dept. of Endocrinology, Diabetes Foot Ulcer Clinic</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ängelholm Hospital, Dept. of Medicine, Diabetic Foot Ulcer Clinic</name>
      <address>
        <city>Ängelholm</city>
        <zip>262 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <results_first_submitted>May 17, 2016</results_first_submitted>
  <results_first_submitted_qc>August 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2016</results_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 18-01-2011 (FPI) to 14-01-2013 (LPO)
Non -ischemic Wagner grade 1 or 2 diabetic foot ulcer (DFU) with a duration of more than 6 weeks and a maximal area of 10 cm2
Patients with &gt; 40% ulcer area change during a two-week run-in period were excluded.</recruitment_details>
      <pre_assignment_details>16 patients were excluded during run-in period: &gt;40% ulcer area reduction n=5 HbA1c &gt; 12% n=3 haemoglobin &lt; 9,5% g/dl, n=1 ulcer area &gt; 10 cm2, n=1 amputation n=1 withdrawn consent, n=2 Osteomyelitis n=1 wrongly included n=2</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LeucoPatch Treatment of Diabetic Foot Ulcers</title>
          <description>Weekly LeucoPatch treatment of diabetic foot ulcers</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44">ITT</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39">Per Protocol (PP)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>hospitalised</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>osteomyelitis</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-adherence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LeucoPatch Treatment of Diabetic Foot Ulcers</title>
          <description>Weekly treatment
LeucoPatch device: weekly treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>All</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="58" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m2)</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" lower_limit="25.6" upper_limit="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of neuropathy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ulcer duration (weeks)</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="16" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ulcer area</title>
          <units>cm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" lower_limit="0.5" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wagner classification</title>
          <description>The Wagner classification is based mainly on wound depth and consists of 6 wound grades. These include: grade 0 (intact skin), grade 1 (superficial ulcer), grade 2 (deep ulcer to tendon, bone, or joint), grade 3 (deep ulcer with abscess or osteomyelitis), grade 4 (forefoot gangrene), and grade 5 (whole foot gangrene).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Wagner grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wagner grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry Haemoglobin</title>
          <units>g/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126" lower_limit="114" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry</title>
          <units>10^9 cells/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262" lower_limit="225" upper_limit="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" lower_limit="6.2" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" lower_limit="6.2" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>mmol/mol</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="55" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Ulcer Healing Within 12 Weeks.</title>
        <description>Number of the patients achieved complete epithelialisation at 12 weeks (ITT population) and the percentage respectively in the PP population</description>
        <time_frame>12 weeks</time_frame>
        <population>Complete epithelialisation was achieved in 15 patients (34%) in ITT population and 38% in the PP population</population>
        <group_list>
          <group group_id="O1">
            <title>LeucoPatch</title>
            <description>LeucoPatch: weekly treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Ulcer Healing Within 12 Weeks.</title>
          <description>Number of the patients achieved complete epithelialisation at 12 weeks (ITT population) and the percentage respectively in the PP population</description>
          <population>Complete epithelialisation was achieved in 15 patients (34%) in ITT population and 38% in the PP population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Healed ITT; n=44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Healed PP; n=39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ulcer Healing Within 20 Weeks</title>
        <description>Number of the patients achieved complete epithelialization at 20 weeks in the ITT population and in the PP population.</description>
        <time_frame>20 weeks</time_frame>
        <population>Number of the patients achieved complete epithelialisation at 20 weeks in the ITT population and in the PP population</population>
        <group_list>
          <group group_id="O1">
            <title>LeucoPatch</title>
            <description>LeucoPatch: weekly treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Ulcer Healing Within 20 Weeks</title>
          <description>Number of the patients achieved complete epithelialization at 20 weeks in the ITT population and in the PP population.</description>
          <population>Number of the patients achieved complete epithelialisation at 20 weeks in the ITT population and in the PP population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Healed ITT; n=44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Healed PP; n=39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Patients Consenting to be Enrolled in the Study.</title>
          <description>60 patients were included for a 2 week run-in period. If ulcer area decreased more than 40% during that time the ulcer were deemed &quot;healing&quot; and NOT included for treatment. 16 patients were excluded during the run-in period - 44 were treated. For safety analysis all patients were included</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Amputation</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Low haemoglobin">SAE not related to Leucopatch treatment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>SAE not related to Leucopatch treatment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title vocab="death">SAE not related to Leucopatch treatment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SAE not related to Leucopatch treatment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Pneumonia">SAE not related to Leucopatch treatment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title vocab="Colonscopy">SAE not related to Leucopatch treatment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>SAE not related to Leucopatch treatment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>necrotic tissue</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Anaemia">AE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title vocab="Bleeding">AE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title vocab="Dizziness">AE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>AE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>AE</sub_title>
                <description>Not taken medication</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>AE</sub_title>
                <description>Problem blood taking</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>AE</sub_title>
                <description>Device related problems</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title vocab="Penicillin treatment">AE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title vocab="Device crash">AE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="Maggot in wound">AE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="Leucopatch Treatment">AE</sub_title>
                <description>Two weeks between treatments</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AE</sub_title>
                <description>Hypertension medication stop</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>AE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title vocab="Low kidney function">AE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>AE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title vocab="New ulcer">AE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>AE</sub_title>
                <description>Stinging sensation in wound area</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title vocab="Erysipelas">AE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>AE</sub_title>
                <description>Increase in exudate</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title vocab="Osteomylitis">AE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>AE</sub_title>
                <description>Blister after footbath</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title vocab="Femur fractur">AE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>MD, PhD Senior Consultant Magnus Löndahl</name_or_title>
      <organization>Reapplix Blokken 45 3460 Birkerød Denmark</organization>
      <email>magnus.londahl@med.lu.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

